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The heart has a limited ability to regenerate. It is important to identify therapeutic
strategies that enhance cardiac regeneration in order to replace cardiomyocytes lost
during the progression of heart failure. Cardiac progenitor cells are interesting targets for
new regenerative therapies because they are self-renewing, multipotent cells located in
the heart. Cardiac side population cells (cSPCs), the first cardiac progenitor cells identified
in the adult heart, have the ability to differentiate into cardiomyocytes, endothelial cells,
smooth muscle cells, and fibroblasts. They become activated in response to cardiac
injury and transplantation of cSPCs into the injured heart improves cardiac function.
In this review, we will discuss the current literature on the progenitor cell properties
and therapeutic potential of cSPCs. This body of work demonstrates the great promise
cSPCs hold as targets for new regenerative strategies.
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INTRODUCTION
Heart failure remains a pressing healthcare problem because of its increasing prevalence and high
rate of morbidity andmortality (Roger et al., 2004; Heidenreich et al., 2013). Loss of cardiomyocytes
during the progression of heart failure is a critical problem that limits the efficacy of current
therapeutic approaches. Consequently, multiple strategies to replace lost cardiomyocytes with
healthy ones are actively being pursued. One innovative strategy is to enhance endogenous cardiac
regeneration, the heart’s innate ability to generate new cells, by activating residential cardiac cells to
proliferate and differentiate into cardiomyocytes.
Cardiac progenitor cells are excellent targets for these therapeutic strategies because they
are multipotent, self-renewing cells that reside in the adult heart. Different populations of
cardiac progenitor cells have been identified primarily based on their expression of specific
cell surface proteins. Recently, we and others employed genetic lineage-tracing models to
demonstrate that c-kit+ cells, the most extensively studied cardiac progenitor cells, have
a limited ability to differentiate into cardiomyocytes in vivo under homeostatic conditions
(van Berlo et al., 2014; Sultana et al., 2015; Liu et al., 2016). These findings make it that
much more important to assess the regenerative capacity of other cardiac progenitor cell
populations, which remain promising targets for new heart failure therapies because of their
unique properties. First, cardiac progenitor cells are multipotent; they can differentiate into
the main types of cells in the heart: cardiomyocytes, endothelial cells, fibroblasts, and smooth
muscle cells. Second, cardiac progenitor cells reside in the heart, opening up the possibility
to develop targeted therapies that activate these cells in vivo circumventing problems like
poor engraftment and immune rejection faced by other cellular therapies. Third, cardiac
progenitor cells self-renew to maintain a pool of undifferentiated clones in the heart that
Yellamilli and van Berlo Side Population Cells in Cardiac Regeneration
is ready to be activated in response to specific stimuli. These key
properties mean that cardiac progenitor cells are a responsive
population of self-renewing cells, residing in the heart, which
can differentiate into the main cardiac lineages. For this reason,
it is important to critically evaluate the therapeutic potential of
cardiac progenitor cells.
Cardiac side population cells (cSPCs) were the first population
of cardiac progenitor cells identified in the heart that possess the
three key progenitor cell properties discussed above (Hierlihy
et al., 2002). Importantly, cSPCs are distinct from c-kit+
cells; they do not express the c-kit protein and c-kit+ cells
do not display the side population phenotype (Pfister et al.,
2005; Unno et al., 2012). Furthermore, microarray analysis
performed on c-kit+ cells and cSPCs demonstrated that they
have distinct transcriptional profiles (Dey et al., 2013). In this
review, we will discuss research that established the progenitor
cell properties of cSPCs and will highlight the remaining gaps in
our understanding of cSPCs that need to be addressed in order to
determine the therapeutic potential of cSPCs.
MOLECULAR BASIS OF THE SIDE
POPULATION PHENOTYPE
The side population phenotype was first described in 1996, as a
way to enrich for hematopoietic stem cells from the bone marrow
of adult mice (Goodell et al., 1996). This phenotype identifies cells
that have the ability to extrude Hoechst 33342, a cell-permeable,
fluorescent, DNA-binding dye, out of the cell through ATP-
binding cassette (ABC) superfamily transporters. To isolate side
population cells, a single cell suspension from a tissue of interest
is incubated withHoechst 33342, which passively diffuses into the
cytoplasm of all cells (Golebiewska et al., 2011). A small number
of the stained cells have the ability to extrude Hoechst 33342 out
of their cytoplasm. These low-Hoechst staining cells are called
side population cells because they appear to the side of the high-
Hoechst staining cells on a flow cytometry plot (Figure 1). To
ensure accurate identification of side population cells, a portion
of the Hoechst-stained single cell suspension is also incubated
with a chemical that blocks the side population phenotype, such
as verapamil (Figure 2; Ambudkar et al., 1999; Montanaro et al.,
2004; Sarkadi et al., 2006; Golebiewska et al., 2011).
Since the identification of side population cells in the bone
marrow, the side population phenotype has been used to identify
stem cells and progenitor cells in tissues throughout the body
(Goodell et al., 1996; Jackson et al., 1999; Asakura et al., 2002;
Hierlihy et al., 2002; Dekaney et al., 2005; von Furstenberg
et al., 2014). In 2002, side population cells were identified in
the heart, demonstrating, for the first time, the existence of a
pool of residential progenitor cells in the adult heart (Hierlihy
et al., 2002). These cells were called cardiac side population
cells (cSPCs). Correct identification of cSPCs is dependent on
proper digestion of cardiac tissue, accurate cell counts, optimal
Hoechst 33342 concentration and precise flow cytometry gating
for side population cells (Montanaro et al., 2004). In the adult
murine heart, cSPCs account for 0.8–2% of non-cardiomyocytes;
however, the number of cSPCs in the heart varies with age
(Hierlihy et al., 2002; Martin et al., 2004; Pfister et al., 2005;
Oyama et al., 2007; Liang et al., 2010; Noseda et al., 2015). For
example, in rats, the number of cSPCs decreases with age, from
4% of non-cardiomyocytes in the fetal heart to 2% in the neonatal
heart to 1.2% in the adult heart (Oyama et al., 2007). A similar
trend has been observed in humans. In the human fetus, cSPCs
account for 1.1% of non-cardiomyocytes; while they account
for 0.22% of non-cardiomyocytes in the left atrium of the adult
heart (Alfakir et al., 2012; Sandstedt et al., 2012). Surprisingly,
this declining trend in numbers of cSPCs reverses later in life,
as a recent study demonstrated an increase in cSPCs in aged
hearts, noting a 2.3-fold higher number of cSPCs normalized to
cardiac mass in 24- to 32-month-old mice compared to 6- to
10-month-old mice (Mulligan et al., 2011).
The side population phenotype is regulated by two ABC
superfamily transporters: P-glycoprotein and ABC sub-family G
member 2 (Abcg2). Originally, P-glycoprotein and Abcg2 were
identified as proteins that confer chemoresistance by extruding
drugs out of the cytoplasm of cancer cells (Juliano and Ving,
1976; Doyle and Ross, 2003). They are also responsible for the
eﬄux of xenobiotics, metabolites, and hormones out of cells in
the placenta, blood-brain barrier, intestines, kidney, and liver
(Schinkel et al., 1994, 1997; Stacy et al., 2013). Of particular
interest to this review, P-glycoprotein and Abcg2 are responsible
for the side population phenotype in the bone marrow and heart.
In bone marrow side population cells, Abcg2 is the exclusive
regulator of the side population phenotype (Figure 2; Zhou
et al., 2001, 2002; Scharenberg et al., 2002; Jonker et al., 2005).
When the genes that encode P-glycoprotein are knocked out,
the number of bone marrow side population cells is not reduced
compared to wild-type controls (Zhou et al., 2001). Conversely,
all bone marrow side population cells are lost when Abcg2 is
knocked out (Zhou et al., 2002). Additionally, when Saos-2 cells,
HEK-293, or C2C12 cells overexpress Abcg2, they acquire the
side population phenotype indicating that Abcg2 is sufficient
to confer this phenotype (Scharenberg et al., 2002; Zhou et al.,
2002; Martin et al., 2004). In cSPCs, there is an intricate, age-
dependent interplay between Abcg2 and P-glycoprotein (Zhou
et al., 2002; Pfister et al., 2008). In the neonatal murine heart,
Abcg2 is the primary regulator of the side population phenotype.
However, as mice age, the role of P-glycoprotein increases until
it becomes the primary transporter responsible for the side
population phenotype in adult murine cSPCs (Pfister et al., 2008).
It is not surprising that both P-glycoprotein and Abcg2 work
together to confer the side population phenotype in cSPCs since
there is significant overlap between P-glycoprotein and Abcg2
substrates in other cells (Dean et al., 2005; Stacy et al., 2013).
PROGENITOR CELL PROPERTIES OF
CSPCS
cSPCs Are Multipotent
They have the ability to differentiate into four major cell types
in the heart: cardiomyocytes, endothelial cells, fibroblasts,
and smooth muscle cells (Table 1). Several different in
vitro approaches have been used to differentiate cSPCs into
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FIGURE 1 | Isolation of side population cells. A single cell suspension is isolated and stained with Hoechst 33342. A small percentage of cells are able to extrude
Hoechst 33342 out of the cytoplasm through ABC transporters. To identify side population cells, the suspension is analyzed on a flow cytometer (Goodell et al., 1996).
The side population cells (red gate) appear to the left side of the main population of cells.
FIGURE 2 | Flow cytometry analysis of side population cells. Bone marrow side population cells can be identified by Hoechst 33342 fluorescence (cells within
the red gate; Goodell et al., 1996). A sample stained with both Hoechst 33342 and Verapamil, which blocks the side population phenotype, is used to ensure
accurate gating and identification of side population cells. In Abcg2 knockout mice, no side population cells are identified (Zhou et al., 2002).
cardiomyocytes (Pfister et al., 2005; Oyama et al., 2007;
Yamahara et al., 2008; Lushaj et al., 2012; Belian et al., 2015).
When cSPCs are co-cultured with adult rat ventricular
cardiomyocytes, they differentiate into cardiomyocytes
that are structurally and functionally comparable to adult
cardiomyocytes. The cSPC-derived cardiomyocytes electrically
couple with surrounding adult rat ventricular cardiomyocytes,
express cardiomyocyte specific proteins, and have well-
organized sarcomeres. Importantly, their contractility and
calcium dynamics when paced are similar to isolated adult
cardiomyocytes. Furthermore, fusion between cSPCs and the
adult rat ventricular cardiomyocytes was ruled out by co-
culturing Green Fluorescent Protein (GFP)-labeled cSPCs with
Red Fluorescent Protein (RFP)-labeled adult rat ventricular
cardiomyocytes. No double fluorescent cardiomyocytes were
observed indicating absence of fusion. Additionally, treatment
of cSPCs in culture with Oxytocin or Trichostatin A, without
co-culturing with adult cardiomyocytes, was sufficient to
generate cSPC-derived cardiomyocytes that express key
cardiac proteins, have highly-organized sarcomeres and beat
spontaneously.
cSPCs also have the ability to differentiate into endothelial
cells and smooth muscle cells. When cSPCs are cultured with
VEGF or a cocktail of pro-angiogenic factors including VEGF,
they begin to express the endothelial markers vWF, CD31,
Angiopoietin 1, and Angiopoietin 2 (Yoon et al., 2007; Liang
et al., 2010, 2011; Lushaj et al., 2012). After 2 weeks in cell culture,
cultured cSPCs form a network of tubular structures (Liang
et al., 2011). cSPCs also express the smooth muscle marker,
α-smooth muscle actin (α-SMA), when they are cultured with
VEGF (Lushaj et al., 2012). When cSPCs were injected into
m. quadriceps 1 day after ligation of the left femoral artery, the
injected cells engraft, and remain in the tissue for 4 weeks. A small
portion of the injected cells expressed endothelial and smooth
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TABLE 1 | In vitro and In vivo differentiation methods for cSPCs.
Cardiac lineages In vitro differentiation method In vivo differentiation method
Cardiomyocytes 1. Co-culture with adult rat ventricular cardiomyocytes (Pfister et al., 2005) 1. Cryoinjury (Oyama et al., 2007)
2. Co-culture with neonatal rat ventricular cardiomyocytes (Yamahara et al., 2008) 2. Myocardial Infarction (Liang et al., 2010)
3. Trichostatin A (Oyama et al., 2007)
4. Oxytocin (Oyama et al., 2007; Emmert et al., 2013)
5. Dexamethasone (Lushaj et al., 2012)
6. MYOCD and TBX5 (Belian et al., 2015)
Endothelial cells 1. VEGF (Yoon et al., 2007; Lushaj et al., 2012) 1. Cryoinjury (Oyama et al., 2007)
2. EGF, VEGF, IGF-1, bFGF, Hydrocortisone, and Ascorbic Acid (Liang et al., 2011) 2. Myocardial Infarction (Liang et al., 2010)
3. Ischemic Limb Injury (Yoon et al., 2007)
Smooth muscle cells 1. VEGF (Lushaj et al., 2012) 1. Cryoinjury (Oyama et al., 2007)
2. Ischemic Limb Injury (Yoon et al., 2007)
Fibroblasts – 1. Cryoinjury (Oyama et al., 2007)
Non-cardiac lineages In vitro
Adipocytes 1. MDI-I Mixture (Oyama et al., 2007)
2. Adipogenic induction medium (Cambrex Biosciences; (Yamahara et al., 2008))
Osteocytes 1. β-glycerolphosphate, Dexamethasone, Ascorbic acid-2 Phosphate (Oyama et al., 2007)
2. BMP2 (Yamahara et al., 2008)
Hematopoietic cells 1. Methylcellulose media (Hierlihy et al., 2002)
Multiple in vitro methods have been used to differentiate cSPCs into the main cardiac lineages found in the heart, as well as other non-cardiac lineages. In the injured heart, transplanted
cSPCs have the ability to differentiate into cardiomyocytes, endothelial cells, fibroblasts, and smooth muscle cells.
muscle markers, vWF, and α-SMA, respectively. Consequently,
there was increased revascularization and blood flow to the
limb, which led to a statistically higher level of limb salvage in
the cSPC-injected mice compared to the saline-injected controls
(Yoon et al., 2007).
In addition to having the ability to differentiate into cardiac
cells, cSPCs can differentiate into extra-cardiac cell types such as
osteocytes, adipocytes, and hematopoietic cells. When cSPCs are
cultured with BMP2 or a combination of β-glycerolphosphate,
Dexamethasone, and Ascorbic Acid-2 Phosphate, they start to
express alkaline phosphatase mRNA and protein, a molecular
marker used to identify osteoclasts (Oyama et al., 2007; Yamahara
et al., 2008). cSPCs can also differentiate into adipocytes when
they are cultured in adipogenic media (Oyama et al., 2007;
Yamahara et al., 2008). Furthermore, when cSPCs are cultured
in methycellulose media, they form granulocyte-macrophage
colony forming units that express Mac-1 and Gr-1(Asakura and
Rudnicki, 2002; Hierlihy et al., 2002).
cSPCs Reside in the Postnatal Heart
To determine whether cSPCs are residential cells in the heart and
not a population of bone marrow-derived cells that translocate
into the heart; newborn mice were lethally irradiated, and then
transplanted with GFP-labeled bone marrow. When the mice
were 12 weeks old, <1% of cSPCs were labeled with GFP
indicating that cSPCs do not arise postnatally from the bone
marrow (Mouquet et al., 2005). Furthermore, cSPCs have a
distinct expression profile from side population cells isolated
from the bone marrow. Cultured cSPCs express important
cardiomyocyte transcription factors, GATA4, andMEF2C, as well
as cardiomyocyte contractile proteins α-actinin and troponin
I. Bone marrow side population cells do not express these
proteins under the same culturing conditions. Furthermore,
freshly isolated cSPCs do not express CD45 or c-kit, which are
both expressed in bone marrow side population cells (Pfister
et al., 2005). After injury, however, there is evidence that bone
marrow cells can contribute a small percentage to cSPCs and
cardiomyocytes (Jackson et al., 2001; Mouquet et al., 2005).
CSPCs are located in specialized niches within the heart.
Since the main method of identifying cSPCs utilizes their ex
vivo phenotype, immunofluorescent staining was performed to
identify the precise location of Abcg2+CD31− cells in the heart.
Ninety-five percent of Abcg2+CD31− cells were located in the
perivascular area and 5% were located in the interstitial space
between cardiomyocytes. There was no difference in the location
of Abcg2+CD31− cells in the base, middle and apex of the heart.
Furthermore, Abcg2+CD31− cells expressed both N-cadherin
and CD29, which are proteins thought to regulate the interaction
of stem cells and progenitor cells with surrounding cells in their
niche (Oyama et al., 2007). These data suggest that cSPCs reside
in a specific niche, which likely controls their proliferation and
differentiation.
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While it is clear that cSPCs are residential cells in the postnatal
heart, their developmental origins remain unclear. One study
identified a potential neural crest origin of cSPCs; while another
suggested a cardiac mesodermal origin of cSPCs (Tomita et al.,
2005; Noseda et al., 2015). The first study demonstrated that
cSPCs have the ability to form spheres in non-adherent culture,
called cardiospheres. When cardiospheres, which were generated
from all non-cardiomyocytes, not from cSPCs, were implanted
into chicken embryos they behaved like cardiac neural crest
cells, and homed to the heart. Subsequently, when neural crest
cells are lineage-traced they give rise to labeled cardiomyocytes,
suggesting that cSPCs are derived from neural crest cells.
However, these data provide only inferred evidence that cSPCs
are of neural crest origin. The second study used genetic lineage-
tracing with multiple Cre lines to identify a cardiac mesodermal
origin of cSPCs. Close to 96% of cSPCs were derived fromMesp1-
expressing cells, while 50–55% were derived from Nkx2-5- or
Isl1-expressing cells (Noseda et al., 2015). Furthermore, 50% of
cSPCs were marked as coming from GATA5-expressing cells,
suggesting a potential pro-epicardial origin during development.
More studies are clearly needed to establish the developmental
origins of cSPCs, which could help uncover important pathways
regulating the proliferation and differentiation of cSPCs.
cSPCs Self-Renew through Clonal
Expansion
When cSPCs were first identified, their clonal properties were
demonstrated by their ability to form colonies when co-cultured
with neonatal rat ventricular myocytes in methylcellulose media
(Hierlihy et al., 2002). Subsequent studies demonstrated that
cSPCs can form colonies when cultured in methylcellulose media
alone—in the absence of neonatal rat ventricular myocytes
(Asakura and Rudnicki, 2002; Martin et al., 2004; Pfister et al.,
2005; Liang et al., 2011; Noseda et al., 2015). More importantly,
these studies demonstrated that cSPCs formed at least 10 times
as many colonies when compared to other non-cardiomyocytes,
indicating that cSPCs have the greatest potential for clonal
expansion in the heart (Asakura and Rudnicki, 2002; Pfister
et al., 2005; Liang et al., 2011; Noseda et al., 2015). To
more critically evaluate the self-renewal properties of cSPCs,
primary and secondary clones derived from cSPCs cultured
in methylcellulose, were propagated and studied for over 10-
months. Importantly, these clones retained the side population
phenotype, expressed stem cell antigen-1 (Sca-1), and did not
undergo replicative senescence (Noseda et al., 2015). Taken
together, these in vitro studies provide evidence that cSPCs
undergo clonal expansion to self-renew their population, an
important feature of cardiac progenitor cells.
ACTIVATION OF CSPCS
Abcg2 Regulates Activation of cSPCs
In addition to regulating the side population phenotype of cSPCs,
Abcg2 is a critical regulator of cSPC proliferation, survival,
and cardiomyocyte differentiation. Knockout of Abcg2 decreases
proliferation of cSPCs in cell culture compared to wild-type
cSPCs evidenced by decreased total cell numbers, DNA content,
protein content, and Ki-67 and phospho-histone H3 staining
(Pfister et al., 2008; Sereti et al., 2013). Abcg2 gene deletion results
in upregulation of mRNA expression of cell cycle inhibitors,
decreased expression of cell cycle activators, and increased cell
cycle duration with more cSPCs in the G0/G1 phase and fewer
cSPCs in S or G2/M phases. Additionally, the percentage of
cSPCs that undergo asymmetrical cell division increases when
Abcg2 is knocked out (Sereti et al., 2013). Consequently, over-
expression of Abcg2 increases the total number of cSPCs in cell
culture (Pfister et al., 2008). Abcg2 also plays a crucial role in the
survival of cSPCs at baseline and in response to oxidative stress
(Pfister et al., 2008; Sereti et al., 2013; Maher et al., 2014). When
Abcg2 is knocked out, cultured cSPCs undergo a greater level
of necrosis and apoptosis under baseline culturing conditions
(Pfister et al., 2008). Additionally, Abcg2 knockout cSPCs express
higher levels of DNA-damage response genes (Sereti et al.,
2013). When these cSPCs are challenged by hydrogen-peroxide
treatment, they also have increased cell death compared to
wild type cSPCs (Pfister et al., 2008). Finally, Abcg2 regulates
the ability of cSPCs to differentiate into cardiomyocytes. While
knockout of Abcg2 does not affect cardiomyocyte differentiation
of cSPCs, overexpression of Abcg2 decreases the ability of
cSPCs to differentiate into cardiomyocytes when they are co-
cultured with adult rat ventricular cardiomyocytes (Pfister et al.,
2008). Taken together, these studies demonstrate the integral
role of Abcg2 in the self-renewal, survival, and cardiomyocyte
differentiation of cSPCs. However, the exact mechanisms by
which Abcg2 regulates these properties have not been established.
cSPCs Are Activated in Response to
Cardiac Injury
Since cSPCs are progenitor cells that reside in the heart and
have multi-lineage differentiation potential, it is important to
determine whether these cells become activated in response to
injury. In the murine cryoinjury model of cardiac injury, there
was a 3-fold increase in the percentage of cSPCs 3 days after
injury. Over the following 2 weeks, the percentage of cSPCs
declined but did not return to baseline levels. None of the cSPCs
expressed CD45, suggesting that the increase in the percentage
of cSPCs was due to proliferation of residential cSPCs and
not the result of infiltration of circulating cells that adopt the
side population phenotype (Martin et al., 2008). In the more
clinically relevant model of experimental myocardial infarction
(MI), ligation of the left anterior descending coronary artery led
to an acute drop in the number of cSPCs in both the infarct
and remote regions of the heart 1 day after injury. Over the
next 7 days, the numbers of cSPCs gradually increased back
to the number in the sham-operated hearts. The restoration
of the numbers of cSPCs after MI was primarily the result of
proliferation of residential cSPCs with a small contribution from
the bone marrow (Mouquet et al., 2005).
Activation of cSPCs in response to cardiac injury was
confirmed in human cardiac tissues. Since Abcg2 is also
expressed by endothelial cells in the human heart, cSPCs were
identified as Abcg2+CD31− cells using immunohistochemical
staining (Meissner et al., 2006; Emmert et al., 2013). With this
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method of identifying cSPCs, the study found an increase in
Abcg2+CD31− cells in both atria and ventricles of ischemic
myocardial samples compared to non-ischemic myocardial
samples from patients with other forms of cardiovascular diseases
like idiopathic dilated cardiomyopathy or valvular heart disease
(Emmert et al., 2013). These findings suggest that myocardial
ischemia in the human heart creates a unique environment
that enhances the proliferation of cSPCs, similar to cryoinjury
in the mouse. Another study demonstrated that therapeutic
intervention could also affect the percentage of cSPCs in the
human heart. This study utilized Abcg2 staining to identify cSPCs
in the setting of chronic heart failure. The number of Abcg2+
cells increased in hearts from the time that left ventricular assist
devices (LVADs) were implanted to the time the LVADs were
removed at the time of cardiac transplantation (Wohlschlaeger
et al., 2012). Taken together, these findings indicate that cSPCs in
the human heart are responsive to cardiac injury and therapeutic
intervention.
To study the in vivo response of cSPCs to cardiac injury,
an Abgc2-driven, tamoxifen-inducible, lineage-tracing mouse
model was used to trace cSPCs in vivo after ischemic cardiac
injury. In theory, this model would allow the proliferation
and differentiation of cSPCs to be identified in vivo without
using their ex vivo phenotype. Unfortunately, initial experiments
demonstrated limited labeling efficiency, with only 2% of bone
marrow side population cells and differentiated blood lineages
derived from bone marrow side population cells labeled (Fatima
et al., 2012). More importantly, labeling of cSPCs was not
determined (Fatima et al., 2012; Maher et al., 2014; Doyle
et al., 2016). Since Abcg2 is the sole regulator of the side
population phenotype in bone marrow side population cells
and not in cSPCs, it is difficult to imagine that there was
robust labeling of cSPCs. Despite these limitations, this model
was used to determine the in vivo role of cSPCs to cardiac
renewal and regeneration. In the embryonic heart, Abcg2-lineage
traced cells gave rise to cardiomyocytes, endothelial cells, and
vascular smooth muscle cells. After birth, there was a rapid
decline in the number of lineage-traced cardiomyocytes, but the
number of lineage-traced endothelial cells remained the same.
One-month after ischemia-reperfusion injury, no lineage-traced
cardiomyocytes were observed. These findings suggest that cSPCs
contribute cardiomyocytes to the embryonic heart but not to
the postnatal heart. However, with the limited labeling of bone
marrow side population cells and without knowing the labeling
efficiency of cSPCs, it is impossible to conclusively determine the
in vivo regenerative potential of cSPCs from these studies.
Specific Factors Associated with
Cardiovascular Disease Regulate cSPC
Activation
Not much is known about how the environment in the diseased
heart affects activation of cSPCs. One factor that can regulate
cSPC activation is the stiffness of the myocardium. For skeletal
muscle satellite cells, it has been established that substrate
elasticity is critical for muscle stem cell self-renewal (Gilbert
et al., 2010). After myocardial infarction, the scar area is
considerably stiffer than healthy myocardium. It is possible
that this increased stiffness impedes the ability of cSPCs to
self-renew and regenerate the heart. To test this hypothesis,
cSPCs were cultured on substrates with different elasticity.
The rate of cSPC proliferation decreased when cultured on
stiffer substrates. Moreover, when cSPCs were co-cultured with
neonatal rat ventricular cardiomyocytes on stiffer substrates
they showed decreased cardiomyocyte differentiation potential
(Qiu et al., 2015). These results indicate that the stiffness
of the local environment in the injured heart may alter the
regenerative potential of cSPCs. Another factor that can influence
cSPC function is Urotensin II, a peptide whose circulating
levels increase in cardiovascular diseases like heart failure and
hypertension (Russell, 2008). The receptor for Urotensin II and
the precursor for Urotensin, are expressed at the mRNA and
protein level in cSPCs. Treatment of cSPCs with Urotensin II
enhanced their proliferation without altering the cardiomyocyte
differentiation potential of cSPCs (Gong et al., 2011). Pressure
overload injury induced by transverse aortic constriction (TAC)
resulted in upregulation of Urotensin II with a subsequent
increase in the percentage of cSPCs. This increase in cSPCs
was blocked when mice that underwent TAC surgery were
treated with Urantide, a Urotensin II antagonist (Chen et al.,
2014). Although the overall consequence on cardiac function was
not determined, these results indicate that cSPCs proliferate in
response to pressure-overload induced upregulation of Urotensin
II. Taken together, these findings demonstrate that signals from
diseased hearts promote the activation of cSPCs; however,
activated cSPCs are clearly insufficient to completely restore the
injured myocardium.
THERAPEUTIC APPROACHES TO REPAIR
THE INJURED HEART USING CSPCS
To test the potential therapeutic applicability of cSPCs, as
well as their in vivo differentiation capacity, cSPCs have been
transplanted in the setting of cardiac injury. Three main studies
in animal models have been performed (Table 2). Importantly,
all experiments showed differentiation of transplanted cSPCs
into cardiomyocytes, endothelial cells and smooth muscle cells,
indicating their multi-lineage potential in the setting of post-
injury transplantation. In the first approach, cSPCs were isolated
from neonatal rats and labeled with GFP (Oyama et al., 2007).
These GFP-labeled cSPCs were injected into adult male rats
via tail vein injections before cryoinjury of the free wall of
the left ventricle. Four weeks after cSPC transplantation, GFP-
labeled cardiomyocytes, endothelial cells, smooth muscle cells,
and fibroblasts were identified in the border zone. This study
demonstrated the ability of cSPCs to home to the injured
heart and give rise to GFP-labeled cardiac cells. However, the
consequence of cSPC transplantation on cardiac function was
not determined. The second approach also used fluorescently
labeled cSPCs, but these ones were isolated from adult mice.
These cSPCs were injected into the border zone immediately
after coronary artery ligation in C57Bl/6j female mice. This study
further confirmed the multi-lineage potential of cSPCs upon
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TABLE 2 | cSPC Transplantation Studies.
Oyama et al., 2007 Liang et al., 2010 Noseda et al., 2015
Injury model Cryoinjury Coronary artery ligation Coronary artery ligation
Recipient Adult male Wistar rats Adult female C57Bl/6 mice Adult female C57Bl/6 mice
Donor Neonatal GFP-transgenic, syngeneic rats Adult female C57Bl/6 mice Adult male C57Bl/6 mice
Transplanted cells 300,000 cSPCs 150,000 cSPCs labeled with fluorescent dye 250,000 cSPC clones labeled with lentiviral mOrange
Administration route Tail-vein injection Intracardiac injection into border zone Intracardiac injection into border zone
Functional outcomes Not assessed Not assessed ↓ Infarct size
↓ Remodeling
↑ Ejection fraction
Three different approaches have used cSPC transplantation to assess the regenerative ability of cSPCs.
transplantation, but also did not assess whether transplantation
improved cardiac function (Liang et al., 2010). The third
study used clonally derived, fluorescently labeled cSPCs isolated
from adult mice for transplantation studies. These cSPCs were
injected into the border zone immediately after coronary artery
ligation in C57Bl/6 adult female mice. Although the majority of
transplanted cells did not engraft in the heart, the ones that did
engraft differentiated into cardiomyocytes, endothelial cells, and
smooth muscle cells. Two weeks after injury, 10% of remaining
transplanted cells expressed cardiomyocyte markers troponin I
or sarcomeric α-actin, but these cells did not have organized
sarcomeres and were mononucleated. Twelve weeks after injury,
50% of transplanted cells expressed cardiomyocyte markers, had
organized sarcomeric structures and were binucleated displaying
a more mature cardiac morphology. In terms of functional
recovery, 1 day after coronary artery ligation, there was no
difference in cardiac function between vehicle control and cSPC-
derived clones; however, 12 weeks after injury, the hearts injected
with cSPC-derived clones showed higher ejection fractions,
smaller scar sizes and decreased remodeling (Noseda et al.,
2015). Although fusion of injected cells with existing cells was
not entirely ruled out as a possible source of labeling, these
results suggest that the transplanted cSPCs differentiate into
cardiomyocytes that can contribute to cardiac regeneration and
improve cardiac function after myocardial infarction.
A common problem with cell transplantation studies in
the heart is poor long-term engraftment; this is a problem
also faced by cSPC. To overcome the poor engraftment of
transplanted cSPCs, biomedical engineering approaches are
actively being pursued to develop delivery methods that enhance
the viability and engraftment of cSPCs in the heart. One method
involved culturing cSPCs in specialized microwells to promote
the formation of cSPC aggregates of reproducible sizes (Bauer
et al., 2012). The underlying hypothesis was that engrafting
aggregates of cSPCs in the heart would enhance cSPC survival
by mimicking the cell-cell contact experienced in the stem cell
niche. These cSPC aggregates decreased the amount of cell
death that occurred in response to oxidative and reoxygenation
injury in vitro. When these aggregates were transplanted
into the heart after ischemic injury, there was an increased
retention rate of cSPCs compared to controls where the same
number of cells was injected in a single cells suspension. The
effect of the implanted aggregates on cardiac function was not
evaluated. A second approach involved seeding cSPCs onto a
methacrylated gelatin core followed by covering the cells with a
silica hydrogel layer (Cha et al., 2014). While the performance
of these constructs was not evaluated, they did demonstrate
the cSPCs remained viable, proliferated, and were able to
spread out off of the gelatin core onto the surrounding surface.
Whether these constructs improved transplantation rates of
cSPCs or cardiac function after injury was not assessed. These
studies demonstrate that cSPCs can be used in combination
with biomedical engineering approaches to improve the
engraftment rates and potentially the regenerative capacity
of cSPCs.
CONCLUSION
Overall, these studies are very encouraging because they
demonstrate the regenerative properties of cSPCs. They
consistently show that cSPCs can be isolated from the heart and
can differentiate into the main cardiac lineages. Furthermore,
cSPCs are activated in response to cardiac injury and after
transplantation into injured hearts. Taken together, these studies
provide evidence that cSPCs could be promising targets for
regenerative therapies. However, to unequivocally determine the
in vivo regenerative potential of cSPCs, genetic lineage-tracing
studies need to be repeated with a unique cSPC marker. Finally,
if it is demonstrated that cSPCs display progenitor cell properties
in vivo, human studies will need to be performed to assess the
regenerative potential of cSPCs in patients.
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